Partnerships and New Ventures
Over a short period, the OSUCCC – James Drug Development Institute (DDI) has established productive partnerships and out-licensed several drug development projects. These partnerships have high-value potential to bring new therapies to patients. Examples are featured below.
Ohio State Research Discovery Enters Phase I Clinical Testing
September 2019: With support from the DDI, a new targeted oral therapy is being offered as an experimental treatment option for patients with certain advanced cancers, including lymphoma. The OSUCCC – James is one of four cancer centers participating in this national clinical trial sponsored by Prelude Therapeutics. Known only as PRT543 while in testing, this new targeted treatment molecule is among the first in an emerging class of drugs called PRMT5 inhibitors. Led by Robert Baiocchi, MD, PhD, the Ohio State research team was the first to discover PRMT5 as a cancer driver and the first to develop and then report a series of novel molecules to selectively inhibit PRMT5. This entire portfolio of molecules was licensed to Prelude. Read more.
Biosortia Pharmaceuticals (Research Collaboration)
December 2015: Biosortia Pharmaceuticals and the OSUCCC − James entered a collaboration providing cancer researchers with access to novel natural products for the purpose of drug development. In conjunction with the DDI, this collaboration will leverage the screening assays and drug development expertise of OSUCCC − James researchers and Biosortia’s proprietary natural product chemistry to identify new therapies. Read more.
Evotec AG (Research Collaboration)
December 2014: The OSUCCC − James and Evotec AG formed a research collaboration to advance a novel mechanism for engaging the important cancer target, Kras. Through this DDI-managed alliance, novel biological discoveries made at Ohio State will be translated into a state-of-the-art drug discovery project. Read more.
Sirona Therapeutics, Inc. (Spin-Out Company)
June 2014: The DDI led an effort to partner with Venture Therapeutics, Inc., The Ohio State University and the University of Michigan to commercialize an oral patch for delivery of drugs for the treatment of precancerous lesions. Through the creation of a new spin-out venture, Sirona Therapeutics, Ohio State and Venture Therapeutics are collaborating to complete preclinical studies and initiate clinical trials. This collaboration demonstrates how academia and industry can work together to advance therapies to meet important unmet medical needs. Read more.
To learn more about becoming a partner with the DDI, contact us at email@example.com.